Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$14.99B |
$12.86
+0.12%
|
|
BBIO
BridgeBio Pharma, Inc.
BBP-812 is an AAV9 gene therapy candidate for Canavan disease, a gene therapy product.
|
$14.58B |
$76.26
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$14.20B |
$182.94
+0.21%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$14.02B |
$94.92
+3.79%
|
|
GH
Guardant Health, Inc.
Core product category: Guardant Health's liquid biopsy tests (Guardant360 Liquid/Tissue) are the primary offerings.
|
$13.98B |
$112.17
+0.17%
|
|
SOLV
Solventum Corporation
V.A.C. Peel and Place dressing is a wound care device, a core MedSurg product.
|
$13.78B |
$79.54
-1.12%
|
|
PEN
Penumbra, Inc.
Penumbra's core offerings include vascular intervention devices used for thrombectomy and catheter-based clot removal.
|
$13.68B |
$350.85
+0.10%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$13.56B |
$27.76
-7.65%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$13.13B |
$132.38
-0.73%
|
|
RVTY
Revvity, Inc.
Revvity's Diagnostics segment includes diagnostic equipment and instruments.
|
$13.06B |
$112.49
-2.40%
|
|
UNM
Unum Group
Health Insurance products are part of Unum's workplace benefits and risk protections in the employee benefits mix.
|
$12.96B |
$76.09
-1.68%
|
|
FMS
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care manufactures and provides Blood Purification Devices used in dialysis, including the 5008X CAREsystem.
|
$12.88B |
$21.95
+1.48%
|
|
UHS
Universal Health Services, Inc.
UHS has a strong behavioral health care segment offering inpatient and outpatient behavioral health services.
|
$12.72B |
$199.80
-2.15%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$12.66B |
$17.04
-1.36%
|
|
GMED
Globus Medical, Inc.
Orthopedic devices and implants (spinal, ALIF spacers, knee systems) sold for reconstruction.
|
$12.62B |
$93.46
-0.46%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$12.46B |
$205.98
-4.21%
|
|
ALGN
Align Technology, Inc.
Align's Invisalign system, iTero scanners, and direct 3D-printed dental devices are core dental equipment products.
|
$12.43B |
$171.52
+0.03%
|
|
DOC
Healthpeak Properties, Inc.
The CCRCs and healthcare facilities component places Healthpeak in Healthcare Services & Facilities.
|
$12.39B |
$17.84
+2.23%
|
|
TEM
Tempus AI, Inc.
Laboratory Testing & Advisory Services – Tempus provides outsourced laboratory testing and regulatory/advisory support.
|
$12.22B |
$70.31
+2.02%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$12.19B |
$24.54
+1.47%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$12.17B |
$76.29
-1.19%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$11.83B |
$43.99
-3.19%
|
|
GL
Globe Life Inc.
Supplemental health/health insurance products marketed by Globe Life.
|
$11.26B |
$139.00
-0.59%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$11.18B |
$501.63
+1.16%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$10.81B |
$219.73
-1.67%
|
|
RDY
Dr. Reddy's Laboratories Limited
Core business focused on manufacturing and selling generic drugs.
|
$10.76B |
$12.91
-1.34%
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$10.68B |
$68.67
-1.84%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.48B |
$54.62
-0.82%
|
|
ENSG
The Ensign Group, Inc.
ENSG's core business is providing post-acute healthcare services and facilities management (skilled nursing, rehabilitative services, senior living) across facilities.
|
$10.42B |
$180.60
-1.60%
|
|
MOH
Molina Healthcare, Inc.
MOH primarily provides health insurance products (Medicaid, Medicare, Marketplace) including integrated dual-eligible plans.
|
$10.37B |
$191.49
-1.16%
|
|
WBA
Walgreens Boots Alliance, Inc.
Home Health & Hospice – Through CareCentrix and related services, Walgreens provides home health coordination and related care services.
|
$10.36B |
$11.98
|
|
QGEN
Qiagen N.V.
QIAGEN directly manufactures diagnostic instruments (e.g., QIAstat-Dx, QIAcuity, QIAsymphony Connect) and automated platforms.
|
$10.36B |
$47.58
-1.66%
|
Showing page 5 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
